Response to treatment with interferon-alfa in patients with chronic hepatitis C and high titers of -M2, -M4 and -M8 antimitochondrial antibodies;Anticuerpos para particulas submitocondriales (-M2, -M4, -M8) y respuesta al tratamiento con interferón en pacientes con hepatitis crónica C y presencia simultánea de anticuerpos antimitocondriales a título elevado

Revista Espanola de Enfermedades Digestivas

Volumn 91, Issue 3, 1999, Pages 168-174

  Garrido Palma, Guillermo ^a,b   Sanchez Cuenca J M ^a   Olaso, V ^a   Pina, R ^a   Urquijo, J J ^a   Lopez Viedma B ^a   Bustamante, M ^a   Berenguer, M ^a   Berenguer, J ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MITOCHONDRION ANTIBODY; MITOCHONDRION ANTIBODY M2; MITOCHONDRION ANTIBODY M4; MITOCHONDRION ANTIBODY M8; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIBODY TITER; ARTICLE; BILIARY CIRRHOSIS; CASE REPORT; CHOLESTASIS; CHRONIC HEPATITIS; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT CONTRAINDICATION;

ADULT; ANTIVIRAL AGENTS; AUTOANTIBODIES; BIOPSY; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; MIDDLE AGED; MITOCHONDRIA, LIVER; RNA, VIRAL;

EID: 0032777769     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Garrido G, Olaso V, Berenguer J, Klein R, Berg PJ. Anticuerpos para particulas submitocondriales (PSM) en el diagnóstico y pronóstico de la cirrosis biliar primaria (CBP) seropositiva y seronegativa por inmunofluorescencia (IF). Gastroenterol Hepatol 1990;14:29-30.
2. Michieletti P, Wanless IR, Scheiner PJ, Heathcote EJ. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrom of autoimmune cholangitis. GUT 1994;35:260-5.
3. Berg PA, Klein R. Antimitochondrial antibodies in primary biliary cirrhosis and other disorders: definition and clinical relevance. Dig Dis 1992;10:85-101.
4. Klein R, Kloppel G, Berg PA. Antimitochondrial antibody profiles determined at early stages of primary biliary cirrhosis differentiate between benign and proggressive course. J Hepatol 1991;12:21-7.
5. Berg PA, Klein R. Mitochondrial antibody systems in primary biliary cirrhosis. Liver 1995;15:281-93.
6. Berg PA, Klein R. Cholestatic diseases of the liver. Curr Opinion Gastroenterol 1996;12:258-71.
7. Fusconi M, Chaminhead I, Baum H, Pisi E. Heterogeneity of antimitochondrial antibodies with the M2-M4 pattern by immunofluorescence as assessed by Western-Immunoblotting and ELISA. GUT 1988;29:440-7.
8. Lindeborn-Fotinos J, Baum H, Berg PA. Mitochondrial antibodies in primary biliary cirrhosis. Further characterization of the -M2 antigen by immunoblotting, revealing species and non-species specific determinants. Hepatology 1985;5:763-9.
9. Kaplan M. Primary Biliary Cirrhosis 1996;335:1570-80.
10. 2 microglobulin epitope on hepatocytes in chronic C hepatitis upon treatment with interferon. Hepatology 1993;17:372-82.
11. Durandy A, Virelizier JL, Griscelli C. Enhancement by interferon of membrane HLA antigens in patients with combined immunodeficiency ay and defective HAL expression. Clin Exp Immunol 1983;52:173-8.
12. Schattner A. Interferons and autoimmunity. Am J Med Sci 1988;295;523-44.
13. Marcellin P, Pouteau M, Benhamou JP. Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. GUT 1992;33:855-6.
14. D'Amico E, Paroli M, Consoli G. Primary biliary cirrhosis induced by interferon therapy for hepatitis C virus infection. Dig Dis Sci 1995;40:2211-6.
15. Maeda CT, Onishi S, Yamamoto Y. Exacerbation of primary biliary cirrhosis during interferon therapy for chronic hepatitis C. Dig Dis Sci 1995;40:1226-30.
16. Maguire JE, Gresser I, Williams AH. Modulation of expression of MHC antigens in the kidneys of mice by interferon alpha/beta. Transplantation 1990;49:130-4.
17. Berg PA, Klein R, Röcken M. Cytokines in primary biliary cirrhosis. Semin Liver Dis 1998 (en prensa).
18. Yoshikawa M, Tsyi T, Matsumura Y, Ishizaka S. Immunomodulation effects of ursodeoxycholic acid on immune responses. Hepatology 1992;16:358-64.
19. Berg PA, Klein R, Lindeborn-Fotinos J. An ELISA method for detecting antimitochondrial antibodies. Hepatology 1985;6:1244-5.
20. Weber P, Brenner J, Klein R, Klöppel G, Berg P. Characterization and clinical relevance of a new complement-fixing antibody - anti-M8 - in patients with primary biliary cirrhosis. Hepatology 1986;6:553-9.
21. Smith AI. Preparation and conditions for assay of mithocondria. En: Eastbrook RW, Pullman ME, eds. Methods in enzymology X. New York: Academic Press; 1976. p. 81-9.
22. Beechey RB, Hubbard SA, Linnet PE. A simple and rapid method for the preparation of ATPase from submitochondrial particles. Biochem J 1974;148:533-7.
23. Burnette WN. «Western blotting» electrophoretic transfer of proteins from sodium dodecyl-sulphate-polyacrylamide gels to unmodified nitrocellulose protein A. Ann Biochem 1981;112:195-203.
24. Poupon RE, Poupon R, and the UDCA-PBC Study Group Ursodiol for the long term treatment of primary biliary cirrhosis. N Engl J Med 1994. 1243-347.
25. Heathcote EJ, Blendis LM, and the Canadian Multicenter Group. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-56.
26. Jorgensen RA, Dickson ER, Hofmann AF, Lindor KD. Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. GUT 1995;36:935-8.
27. Reddy RR, Poupon R, Opolon P, Homberg J, Schiff ER. Absence of LKM-1 antibody in hepatitis C viral infection in the United States (resumen). Hepatology 1993; 18: 173A.
28. Clifford BD, Donahue D, Manns M, Bonkosky HL. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995;21: 613-9.
29. Pascasio JM, Narváez I, García M, Doblaré E. Autoantibodies in chronic hepatitis. Importance of the autoimmune ethiology. GUT 1996;39(Supl 2):A117.
30. Gregori GV, Jones H, Mieli-Vergani G, Vergani D. Autoantibody prevalence in chronic hepatitis B virus infection: effect of interferon alfa. Hepatology 1996; 24:520-3.
31. Zinckernagel RM. Immunity of viruses. En: Paul WE, ed. Fundamental immunology. New York: Raven Press; 1993. p. 1211-49.
32. Manns MP. Virus hepatotropos y autoinmunidad. Hepatol Clin 1996;4:71-4.
33. Colombato P, Verme G, Thomas HC, Bonino F. Hepatitis G virus RNA in patients with elevated GGT and alkaline phosphatase: a specific liver disease? (resumen). J Hepatol 1996;25:57.
34. Xu L, Guo L, Neuberger J, Perrillo R, Mason A. Viral induction of primary biliary cirrhosis (resumen). J Hepatol 1997;24:147.
35. Water J, Cooper A, Coppel R, Dickson R, Gershwin E. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrosis. N Engl J Med 1989;320:1377-80.
36. Leung PSC, Coppel RL, Muñoz S, Gershwin E. Antimitochondrial antibodies in primary biliary cirrhosis. Semin Liver Dis 1997;1:61-9.
37. Kaji K, Nakamura Y, Sasaki M, Tsureyama M, Gerswin MI. Hepatic bile duct injury in chronic hepatitis C. Histologic and immunohistochemical studies. Med Pathol 1994;9:937-45.
38. Metcalf JV, James OW, Palmer JM. True positive AMA and normal alkaline phosphatase: is this primary biliary cirrhosis? Ten years on, the answer is yes (resumen). GUT 1996;38:A634.
39. Khemissa F, Bauget P, Michel H, Larrey D. Disaparition des auto-anticorps seriques au cours d'un traitement par interferon alpha chez une malade atteinte d'hepatite chronique C. Gastroenterol Clin Biol 1997;12:998-9.
40. 1, from hepatitis C virus-positive and negative sera. Gastroenterology 1993;104:1762-7.
41. Vergani D, Mieli-Vernagi A. Type II autoimmune hepatitis. What is the role of the hepatitis C virus? Gastroenterology 1993;104:1870-3.
42. 1 in autoimmune hepatitis and hepatitis C virus related liver disease. GUT 1995;37:406-13.
43. Marcellin P, Benhamou JP. Autoimmune disorders associated with hepatitis C. In: Boyer JL, Ockner R, eds. Progress in liver diseases. Philadelphia: Saunders; 1995. p. 247-68.
44. x) by western-immunobloting. J Hepatol 1999 (en prensa).
45. Todros L, Saracco G, Verme G, Rizzetto M. Efficacy and safety of interferon alfa therapy in chronic hepatitis C, with antibodies to liver-kidney microsomes. Hepatology 1995;22:1374-8.